慢性腎病曙光！大麻素研究重大突破！
論文來源：
https://doi.org/10.3389/fphar.2026.1777644
Chronic kidney disease (CKD) is a significant health problem around the
world. It can progress towards end-stage renal disease (ESRD), in which the current therapeutic options are dialysis and kidney transplant, which have several challenges in therapy compliance and finding a donor. There is a crosstalk between high blood pressure, diabetes, and obesity, which are the leading causes of CKD. The increased prevalence of these conditions, plus the ageing population, highlights the importance of finding new therapies to prevent and stop the progression of CKD.
慢性腎臟病（CKD）是全球一個重要的健康議題。 CKD可進展至末期腎病（ESRD），目前治療方案主要為透析和腎臟移植，但治療依從性和尋找捐贈者方面存在諸多挑戰。高血壓、糖尿病和肥胖是CKD的主要病因，二者之間有交互作用。這些疾病盛行率的增加以及人口老化，凸顯了尋找預防和阻止CKD進展的新療法的重要性。
At the cellular level, CKD is characterized by the progressive loss of
podocytes in the kidney glomeruli, reducing their filtration capacity. Other hallmarks of CKD are also part of acute kidney injury (AKI) pathogenesis, and both conditions are interlinked. The renal system expresses cannabinoid receptor types 1 and 2 (CB1 and CB2, respectively).
在細胞層面上，CKD的特徵是腎小球足細胞進行性喪失，導致腎小球濾過能力下降。 CKD的其他一些特徵也是急性腎損傷（AKI）發病機制的一部分，兩者之間存在關聯。腎臟系統表達1型和2型大麻素受體（CB1和CB2）。
There is evidence in animal models that targeting the cannabinoid receptors could modulate the progression of CKD and AKI. The role of cannabinoid
signalling has not been sufficiently explored; several receptors that are not fully characterized have emerged as putative cannabinoid receptors
(i.e., GPR55, GPR18, and GPR119), and some have been implicated in kidney pathophysiology. Moreover, cannabinoid receptors also interact and/or
regulate other receptors (e.g., AT1, TRPV1, and PPARγ).
動物模型研究表明，靶向大麻素受體可能調節CKD和AKI的進展。大麻素訊號通路的作用尚未被充分研究；一些尚未完全表徵的受體（例如GPR55、GPR18和GPR119）被認為是潛在的大麻素受體，其中一些與腎臟病理生理學有關。此外，大麻素受體也與其他受體（例如AT1、TRPV1和PPARγ）相互作用和/或調控它們。
Thus, there are several open questions regarding the role that cannabinoid signalling may play in the context of kidney diseases. In this mechanistic review, we examined the pharmacological actions of classic and emerging
cannabinoid receptors on the renal system to identify potential therapeutic targets for kidney disease.
因此，關於大麻素訊號通路在腎臟疾病中的作用，仍有許多懸而未決的問題。在本機制綜述中，我們探討了經典和新興大麻素受體對腎臟系統的藥理作用，旨在識別腎臟疾病的潛在治療標靶。
The glomerulus, the kidney's filtration barrier, includes a glomerular
basement membrane; fenestrated endothelial cells, which feature tiny pores; and podocytes, specialized epithelial cells whose foot-like extensions help filter blood as they wrap around blood vessels. The glomerulus and renal tubules comprise a nephron, the kidney's basic filtering unit.
As CKD progresses, it diminishes the podocyte basement membrane, decreases the proteins nephrin and podocin, interferes with crucial podocyte foot
processes, promotes cell death, and causes tubular fibrosis and collapse.
Interestingly, both glomeruli and renal tubules have been identified as sites of cannabinoid receptors.
腎小球是腎臟的過濾屏障，由腎小球基底膜、具有微小孔隙的窗孔內皮細胞、足細胞組成。足細胞是一種特殊的上皮細胞，其足狀突起包裹血管，有助於過濾血液。腎絲球和腎小管共同構成腎單位，腎單位為腎臟的基本過濾單元。
隨著 CKD 的進展，它會減少足細胞基底膜，降低腎素和足蛋白的含量，幹擾足細胞足突的關鍵功能，促進細胞死亡，並導致腎小管纖維化和塌陷。
有趣的是，腎絲球和腎小管都已被確定為大麻素受體的部位。
"The specific localization of cannabinoid receptors within renal structures, such as glomeruli and tubules, and their physiological actions may reveal their pharmacological utility," the review authors note. "There is evidence in animal models that targeting the cannabinoid receptors could modulate the progression of CKD and AKI [acute kidney injury]."
「大麻素受體在腎臟結構（如腎小球和腎小管）中的特定定位及其生理作用可能揭示其藥理學用途，」該綜述的作者指出。 “動物模型研究表明，靶向大麻素受體可以調節慢性腎臟病和急性腎損傷的進展。”
===(以下碎碎念時間)===
難怪洗腎不可逆，有些藥物往往被主流醫界拖到最後才挖出來研究...
--
劉德華 悟 電影【新少林寺】主題曲 https://youtu.be/dLRLWy7bKS4
作曲：趙欽 作詞：劉德華 《金剛總持祈請文》
編曲：Adam Lee．飾墜．陳德建 蔣巴桑波 (第七世噶瑪巴確扎嘉措之根本上師) 著監製：陳德建．李安修 不要把金王冠織入鳥巢中 招惹微風與獵槍是不明智的依常斷見所立宗 能壞慧命因緣法 精勤十善一夜盡 縱生天人多闡提
--